Rosalind Advisors Inc. Grows Holdings in CG Oncology, Inc. $CGON

Rosalind Advisors Inc. grew its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 55.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 300,000 shares of the company’s stock after buying an additional 107,026 shares during the quarter. CG Oncology accounts for about 4.3% of Rosalind Advisors Inc.’s holdings, making the stock its 10th biggest position. Rosalind Advisors Inc. owned approximately 0.39% of CG Oncology worth $12,084,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Candriam S.C.A. lifted its position in CG Oncology by 35.9% in the 3rd quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock valued at $41,806,000 after acquiring an additional 274,312 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of CG Oncology by 217.6% in the third quarter. Voya Investment Management LLC now owns 47,986 shares of the company’s stock worth $1,933,000 after purchasing an additional 32,877 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after purchasing an additional 670,770 shares during the last quarter. Tejara Capital Ltd bought a new position in shares of CG Oncology in the second quarter valued at approximately $944,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of CG Oncology during the second quarter valued at approximately $676,000. 26.56% of the stock is owned by institutional investors.

Insider Buying and Selling

In other CG Oncology news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.40% of the company’s stock.

CG Oncology Price Performance

Shares of NASDAQ:CGON opened at $62.97 on Friday. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $64.67. The company has a market capitalization of $5.32 billion, a PE ratio of -30.42 and a beta of 1.18. The business has a fifty day moving average price of $54.21 and a two-hundred day moving average price of $44.31.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. Sell-side analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CGON shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Royal Bank Of Canada upped their target price on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Piper Sandler increased their target price on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Finally, Wedbush initiated coverage on shares of CG Oncology in a research report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.00.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.